- Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading ...
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital ...
SHANGHAI, China, September 22, 2025 (EZ Newswire) -- WuXi AppTec, opens new tab marks its 25th anniversary this year as a trusted partner to innovators worldwide. Over the past quarter century, the ...
SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing ...
WuXi Biologics completed the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000 L single-use bioreactors (SUBs) in the second drug substance line of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback